|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US6011146A
(en)
|
1991-11-15 |
2000-01-04 |
Institut Pasteur |
Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
|
|
US5734023A
(en)
|
1991-11-19 |
1998-03-31 |
Anergen Inc. |
MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
US5820866A
(en)
|
1994-03-04 |
1998-10-13 |
National Jewish Center For Immunology And Respiratory Medicine |
Product and process for T cell regulation
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5869270A
(en)
|
1996-01-31 |
1999-02-09 |
Sunol Molecular Corporation |
Single chain MHC complexes and uses thereof
|
|
GB9625640D0
(en)
|
1996-12-10 |
1997-01-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
AU741130B2
(en)
|
1997-09-16 |
2001-11-22 |
Oregon Health Sciences University |
Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
|
|
GB9720054D0
(en)
|
1997-09-19 |
1997-11-19 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6232445B1
(en)
|
1997-10-29 |
2001-05-15 |
Sunol Molecular Corporation |
Soluble MHC complexes and methods of use thereof
|
|
JP4334141B2
(ja)
|
1998-04-20 |
2009-09-30 |
グリカート バイオテクノロジー アクチェンゲゼルシャフト |
抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
|
|
US6818749B1
(en)
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
DE60131456T2
(de)
|
2000-11-30 |
2008-07-10 |
Medarex, Inc., Milpitas |
Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
AU2002368077B2
(en)
|
2001-07-12 |
2010-03-04 |
Jefferson Foote |
Super humanized antibodies
|
|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
GB0315450D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
GB0315457D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
PT1644412E
(pt)
|
2003-07-01 |
2015-12-23 |
Ucb Biopharma Sprl |
Fragmentos de anticorpos fab modificados
|
|
WO2006028936A2
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
WO2008020827A2
(en)
|
2005-08-01 |
2008-02-21 |
Biogen Idec Ma Inc. |
Altered polypeptides, immunoconjugates thereof, and methods related thereto
|
|
DK1999154T3
(da)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
US8748356B2
(en)
|
2007-10-19 |
2014-06-10 |
Janssen Biotech, Inc. |
Methods for use in human-adapting monoclonal antibodies
|
|
AU2008343589A1
(en)
|
2007-12-19 |
2009-07-09 |
Centocor Ortho Biotech Inc. |
Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
JP2012505654A
(ja)
|
2008-10-14 |
2012-03-08 |
ヤンセン バイオテツク，インコーポレーテツド |
抗体をヒト化及び親和性成熟する方法
|
|
DK3178835T3
(da)
|
2009-02-03 |
2019-06-24 |
Amunix Pharmaceuticals Inc |
Forlængede rekombinante polypeptider og sammensætninger omfattende samme
|
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
PT2560993T
(pt)
|
2010-04-20 |
2024-09-16 |
Genmab As |
Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
|
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
KR102049223B1
(ko)
*
|
2010-11-04 |
2019-11-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
항－ｉｌ－２３ 항체
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
TWI736437B
(zh)
|
2010-11-30 |
2021-08-11 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
IN2014CN03887A
(enExample)
|
2011-10-27 |
2015-10-16 |
Genmab As |
|
|
US9574010B2
(en)
|
2011-11-04 |
2017-02-21 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
US9527927B2
(en)
|
2011-12-20 |
2016-12-27 |
Medimmune, Llc |
Modified polypeptides for bispecific antibody scaffolds
|
|
WO2013157953A1
(en)
|
2012-04-20 |
2013-10-24 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
AU2013351542B2
(en)
|
2012-11-28 |
2018-08-09 |
BioNTech SE |
Individualized vaccines for cancer
|
|
MX385344B
(es)
|
2012-11-28 |
2025-03-18 |
Zymeworks Bc Inc |
Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
|
|
CA2906566C
(en)
|
2013-03-14 |
2024-09-10 |
Macrogenics, Inc. |
Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP3587448B1
(en)
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10047167B2
(en)
|
2013-03-15 |
2018-08-14 |
Eli Lilly And Company |
Methods for producing fabs and bi-specific antibodies
|
|
PT2970980T
(pt)
|
2013-03-15 |
2018-11-19 |
Janssen Biotech Inc |
Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
|
|
US10647768B2
(en)
|
2014-05-29 |
2020-05-12 |
Macrogenics, Inc. |
Multi-chain polypeptide-containing tri-specific binding molecules
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
JP6913032B2
(ja)
|
2015-05-20 |
2021-08-04 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
共通ネオ抗原
|
|
WO2017040324A1
(en)
|
2015-08-28 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
|
US20190031785A1
(en)
|
2016-01-13 |
2019-01-31 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
CN109071632B
(zh)
|
2016-02-05 |
2022-12-30 |
奥里尼斯生物科学私人有限公司 |
靶向性治疗剂及其用途
|
|
SG11201808196UA
(en)
|
2016-03-31 |
2018-10-30 |
Neon Therapeutics Inc |
Neoantigens and methods of their use
|
|
WO2017177207A1
(en)
|
2016-04-07 |
2017-10-12 |
Bostongene, Llc |
Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
|
|
US11534496B2
(en)
|
2016-06-07 |
2022-12-27 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
|
|
CN109843926B
(zh)
|
2016-09-30 |
2023-01-20 |
豪夫迈·罗氏有限公司 |
针对cd3的双特异性抗体
|
|
WO2018170096A1
(en)
*
|
2017-03-14 |
2018-09-20 |
Dualogics, Llc |
Use of a cd4/cd8 bispecific antibody for the treatment of diabetes
|
|
WO2018199318A1
(ja)
*
|
2017-04-28 |
2018-11-01 |
国立大学法人高知大学 |
抗ｇｐｃ－１抗体
|
|
CN110997013B
(zh)
*
|
2017-07-24 |
2022-09-20 |
瑞泽恩制药公司 |
抗cd8抗体和其用途
|
|
WO2019033043A2
(en)
*
|
2017-08-11 |
2019-02-14 |
Genentech, Inc. |
ANTI-CD8 ANTIBODIES AND USES THEREOF
|
|
KR20200142525A
(ko)
|
2018-04-05 |
2020-12-22 |
노파르티스 아게 |
암에 대한 삼중특이성 결합 분자 및 이의 용도
|
|
TW202010757A
(zh)
|
2018-04-11 |
2020-03-16 |
美商英伊布里克斯公司 |
具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
|
|
EA202092849A1
(ru)
|
2018-05-24 |
2021-03-16 |
Янссен Байотек, Инк. |
Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
|
|
WO2020060924A1
(en)
*
|
2018-09-17 |
2020-03-26 |
Dualogics, Llc |
Use of a cd4/cd8 bispecific antibody for the treatment of autoimmune/inflammatory disorders
|
|
PH12022551470A1
(en)
|
2019-12-18 |
2023-05-03 |
Janssen Biotech Inc |
Materials and methods for in vivo biological targeting
|
|
KR20230086765A
(ko)
*
|
2020-10-13 |
2023-06-15 |
얀센 바이오테크 인코포레이티드 |
분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
|